Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.50 |
| ▸ | GHSR | Q92847 | 3/20 | 0.44 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.43 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.43 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.43 |
| ▸ | FURIN | P09958 | 6/20 | 0.41 |
| ▸ | NMT2 | O60551 | 1/20 | 0.39 |
| ▸ | NMT1 | P30419 | 1/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23230082 | 1.00 | NOD1 (0.50) | NOD1GHSRERAP2ERAP1LNPEP | |
| SCHEMBL30340325 | 1.00 | NOD1 (0.50) | NOD1GHSRERAP2ERAP1LNPEP | |
| SCHEMBL23230081 | 0.98 | NOD1 (0.49) | NOD1GHSRERAP2ERAP1LNPEP | |
| SCHEMBL20653679 | 0.94 | NOD1 (0.55) | NOD1GHSRERAP2ERAP1LNPEP | |
| SCHEMBL31686179 | 0.94 | NOD1 (0.55) | NOD1GHSRERAP2ERAP1LNPEP | |
| SCHEMBL30602795 | 0.88 | FOLH1 (0.51) | NOD1ERAP2ERAP1LNPEPNMT2 | |
| SCHEMBL23230146 | 0.88 | FOLH1 (0.51) | NOD1ERAP2ERAP1LNPEPNMT2 | |
| SCHEMBL29373136 | 0.88 | FOLH1 (0.51) | NOD1ERAP2ERAP1LNPEPNMT2 | |
| SCHEMBL30300584 | 0.88 | FOLH1 (0.51) | NOD1ERAP2ERAP1LNPEPNMT2 | |
| SCHEMBL30428059 | 0.88 | FOLH1 (0.51) | NOD1ERAP2ERAP1LNPEPNMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360179-A1 | STAPLED PEPTIDES AND METHODS THEREOF | PARABILIS MEDICINES, INC. | 2024-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360179-A1 | STAPLED PEPTIDES AND METHODS THEREOF | CTNNB1, APC, CTNNA1 | NOD1 3280/4885GHSR 1369/4885ERAP2 587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.